CN1203877C - Chinese medicine preparation for curing hemorrhoidal bleeding - Google Patents
Chinese medicine preparation for curing hemorrhoidal bleeding Download PDFInfo
- Publication number
- CN1203877C CN1203877C CN 02113007 CN02113007A CN1203877C CN 1203877 C CN1203877 C CN 1203877C CN 02113007 CN02113007 CN 02113007 CN 02113007 A CN02113007 A CN 02113007A CN 1203877 C CN1203877 C CN 1203877C
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- flos sophorae
- pericarpium citri
- ethanol
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 title abstract 2
- 208000014617 hemorrhoid Diseases 0.000 claims abstract description 67
- 239000008187 granular material Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 235000016993 Agrimonia Nutrition 0.000 claims abstract description 5
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 239000000341 volatile oil Substances 0.000 claims description 42
- 208000032843 Hemorrhage Diseases 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 25
- 208000034158 bleeding Diseases 0.000 claims description 24
- 230000000740 bleeding effect Effects 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 2
- 241001092084 Agrimonia Species 0.000 claims 2
- 241000581682 Sanguisorba Species 0.000 claims 2
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 244000307697 Agrimonia eupatoria Species 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 240000002924 Platycladus orientalis Species 0.000 abstract 1
- 240000004064 Poterium sanguisorba Species 0.000 abstract 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 29
- 201000007772 internal hemorrhoid Diseases 0.000 description 29
- 210000000436 anus Anatomy 0.000 description 28
- 208000035861 hematochezia Diseases 0.000 description 25
- 230000023597 hemostasis Effects 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000008034 disappearance Effects 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 230000008961 swelling Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010020565 Hyperaemia Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 206010068172 Anal pruritus Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000009544 Pruritus Ani Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 210000002255 anal canal Anatomy 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 2
- 244000173853 Sanguisorba officinalis Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010048946 Anal abscess Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038074 Rectal polyp Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000007783 perianal hematoma Diseases 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000022075 polyp of rectum Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- -1 r-glutamyl Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicinal preparation for curing hemorrhoidal bleeding and a preparation method thereof. The present invention is characterized in that six kinds of raw medicinal materials such as sophora flower, fineleaf schizonepeta herb, tangerine peel, Chinese arborvitae twig, garden burnet root and hairyvein agrimonia herb and bud are mixed according to a certain proportion and made into granules by modern extraction, separation and refining techniques. The Chinese medicinal preparation of the present invention has the advantages of reasonable prescription, advanced technology and outstanding curative effect and provides a good medicine for patients with piles.
Description
The invention belongs to a kind of medicine for the treatment of bleeding hemorrhoids, the invention still further relates to the preparation method of this medicine.
The soft arteries and veins group that hemorrhoid are that venous plexus expansion, flexing form under the rectum end mucosa and under the anal canal skin claims hemorrhoid disease, haemorrhoids again, practises claiming hemorrhoid.Because this patient is numerous, dying has saying of " ten having nine hemorrhoid ".The lighter's symptom is very not remarkable, checks and finds through the doctor.That clinical manifestation is generally is hemorrhage, the anus hemorrhoid are deviate from, and it is main swelling and ache etc.
Cause the cause of disease, the pathogenesis multiterminal of bleeding hemorrhoids.Common person such as improper diet, raw food are richly processed, sitting, station, walking for a long time for a long time, so that the internal organs imbalance of YIN and YANG, and the corruption of intestinal mansion is not normal, accumulate temperature, long-pending heat, and it is not smooth defecate, because of the damp invasion of lower energizer anorectal, and the thermal burn yin collaterals, the mad row of heat in blood, blood is not passed through, so the hematochezia of defecating.Not smooth because of local QI-blood circulation, and cause swelling and pain of anus.Damp and hot inner product, the taste abnormal ascending-descending of QI, heat smokes in last then xerostomia, bitter taste, stomach not each, so appetite owes to shake.The intestinal mansion is damp and hot does not dispel, and internal organs gas is not smooth, and big dry stool is long-pending to be difficult to resolve, hematochezia often in the time of just.The etiology and pathogenesis of bleeding hemorrhoids, except that above-mentioned, also relevant with exopathogen such as wind, dry, wet, heat.For another women 's fertility too much, chronic diarrhea chronic dysentery, people's insufficiency of vital energy and blood in old age or other chronic disease, cause deficiency of QI in middle-JIAO, collapse of QI causes proctoptosis, haemorrhoids person, blood is appeared many, causes QI and blood deficiency person.
The object of the present invention is to provide that a kind of to have a removing summer-heat hemorrhoidal hamorrhage damp and hot, the Chinese medicine preparation of the bleeding hemorrhoids of cooling blood for hemostasis.
Another purpose of present inventor provides the preparation method of this bleeding hemorrhoids therapeutic agent.
Medicine of the present invention is because following bulk drugs (weight portion) medicament of making by weight ratio:
1～3 part of 1～3 part of Pericarpium Citri Reticulatae of 1～3 portion of Herba Schizonepetae of Flos Sophorae
1～3 part of 1～3 part of Herba Agrimoniae of 1～3 portion of Radix Sanguisorbae of Cacumen Platycladi.
The method of said medicine being made medicine of the present invention is: Flos Sophorae adopts percolation or infusion process with 0%～90% ethanol extraction, is prepared into fluid extract; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted volatile oil, and volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 1～20, and the aqueous solution behind extraction volatile oil device is in addition deposited; Medicinal residues and Radix Sanguisorbae, Herba Agrimoniae that Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted behind the volatile oil decoct with water 1～4 time, each 0.5～3.5 hour, collecting decoction, filter, aqueous solution behind filtrate and the said extracted volatile oil merges, be 1.01～1.35 to density when being concentrated into hot thermometric degree and being 20～100 ℃, cooling, add the ethanol accent and contain the alcohol amount, place more than 0 hour, get supernatant to 0%～95%, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and relative density is 1.01～1.40 clear paste when being concentrated into hot thermometric degree and being 20～100 ℃; Qinghuo reagent, the inclusion complex of adding adjuvant, volatile oil, mix homogeneously is made granule or tablet or capsule.
The advantage of medicine of the present invention is:
Flos Sophorae in the side, bitter in the mouth is cool in nature, goes into liver, large intestine channel, merit is arrogated to oneself the clearing away heat and cooling blood hemostasis, always with controlling illness such as discharging fresh blood stool, hematuria, metrorrhagia, sore.Modern age, pharmaceutical research showed, Flos Sophorae can make blood capillary keep normal resistance, reduced vascular permeability, had antiinflammatory action.Herba Schizonepetae (stir-fry) is good at hemostasis, and can dispel the wind.Control in single proved recipe of stool hematochezia, much all use medicines such as Flos Sophorae, Herba Schizonepetae, take orally with Flos Sophorae, Herba Schizonepetae two medicines " frying purple be end " as " easy folk prescription ", " through proved recipe " is that the hematochezia etc. of defecating is controlled at the end with Herba Schizonepetae stir-fry simply.Pericarpium Citri Reticulatae is the name Pericarpium Citri tangerinae also, and is hot, bitter, and during temperature, function were regulated the flow of vital energy and transferred, damp eliminating was reduced phlegm, and is the main medicine of damp eliminating in we, the turbid damp of the internal organs of dispelling, and row QI of the spleen and stomach machine wetly goes then to exempt from its strongly fragrant and heat-transformation, wetly goes also to be beneficial to heat clearing away and controls the agent of blood and play a role better.
Cacumen Platycladi hardship, puckery, cold in nature, function is cooling blood for hemostasis, wind-damp dispelling looses and swells and ache.Radix Sanguisorbae hardship, acid, cold in nature, merit is arrogated to oneself cooling blood for hemostasis, heat-clearing and toxic substances removing.Two medicines are blood disorder product commonly used, can control diseases such as haematemesis, epistaxis, hematuria, and to bleeding hemorrhoids, the discharging fresh blood stool function is also excellent.Herba Agrimoniae suffering, hardship, property is flat, and function is stopped blooding, is good for the stomach, and controls spitting of blood, haematemesis, hematuria, has blood in stool, and impairment caused by overstrain is taken off power, wound hemorrhage." BAICAO mirror " once carried this medicine energy, and " therapeutic method to keep the adverse QI flowing downwards is invigorated blood circulation, and controls discharging fresh blood stool." above three medicines, pharmaceutical research also confirmed to have and shortened blood coagulation, bleeding time modern age, made effects such as promotion blood coagulation such as vasoconstriction, and adapted has synergism to removing heat from blood, hemostasis mutually.
Full side's Six-element Chinese medicine phase 5, function removing summer-heat hemorrhoidal hamorrhage is damp and hot, cooling blood for hemostasis, it is hemorrhage to be used for hemorrhoid (comprising internal hemorrhoid, mixed hemorrhoid), discharging fresh blood stool, the scarlet person of color, respond well.By dialectical classification, cure mainly syndrome of stagnant and jamming dampness-heat, show as swelling and pain of anus, constipation with dry stool, hemorrhage after an action of the bowels, color is scarlet, and with dry mouth with bitter taste, appetite owes to shake, yellowish fur, diseases such as sliding number of pulse condition or stringy and rapid pulse.
The optimization formula of preparation medicine of the present invention is:
1.5～2.5 parts of 1.5～2.5 parts of Pericarpium Citri Reticulataes of 1.5～2.5 portions of Herba Schizonepetae of Flos Sophorae
1.5～2.5 parts of 1.5～2.5 parts of Herba Agrimoniaes of 1.5～2.5 portions of Radix Sanguisorbaes of Cacumen Platycladi.
Its preparation method is: Flos Sophorae is made solvent with 0%～95% ethanol, adopts percolation or infusion process, is prepared into fluid extract; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted volatile oil, and volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 1～20, and the aqueous solution behind extraction volatile oil device is in addition deposited; The medicinal residues that Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted behind the volatile oil decoct with water 1-4 time with Radix Sanguisorbae, Herba Agrimoniae, each 0.5～3.5 hour, collecting decoction, filter, aqueous solution behind filtrate and the said extracted volatile oil merges, relative density is 1.01～135 when being concentrated into hot thermometric degree and being 20～100 ℃, cooling, add the ethanol accent and contain the alcohol amount, place more than 0 hour, get supernatant to 0%～95%, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and relative density is 1.01～1.40 clear paste when being concentrated into hot thermometric degree and being 20～100 ℃; Qinghuo reagent, the inclusion complex of adding adjuvant, volatile oil mixes and spares all, makes granule or tablet or capsule.
Preparation 1000g medicine of the present invention takes by weighing raw material by the proportioning of 2 parts in Flos Sophorae, 2 parts of Herba Schizonepetae, 2 parts of Pericarpium Citri Reticulataes, 2 parts of Cacumen Platycladis, 2 parts of Radix Sanguisorbaes, 2 parts of Herba Agrimoniaes:
Flos Sophorae 200g Herba Schizonepetae 200g Pericarpium Citri Reticulatae 200g Cacumen Platycladi 200g Radix Sanguisorbae 200g Herba Agrimoniae 200g
Preparation method is: Flos Sophorae is made solvent with 70% ethanol, adopts percolation, is prepared into the Flos Sophorae fluid extract routinely; The conventional volatile oil that extracts Herba Schizonepetae, Pericarpium Citri Reticulatae and Cacumen Platycladi, volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 8, the aqueous solution behind extraction volatile oil device is in addition deposited; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi is extracted medicinal residues and the Radix Sanguisorbae behind the volatile oil, Herba Agrimoniae decocts with water 2 times, each 2 hours, collecting decoction, filter, the aqueous solution merging behind filtrate and the said extracted volatile oil, relative density is 1.25～1.30 when being concentrated into hot thermometric degree and being 50 ℃, cooling, add the ethanol accent and contain the alcohol amount, place more than 24 hours, get supernatant to 60%, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and when being concentrated into hot thermometric degree and being 50 ℃ be 1.30～1.33 clear paste density, qinghuo reagent, add adjuvant, the inclusion complex of volatile oil, mix homogeneously is made granule or tablet or capsule.
For showing the therapeutic effect of the present invention to bleeding hemorrhoids, the present invention selects 100 examples suitable with test group such as medical history, sex, age, the course of disease, sick kind, state of an illness program, complication to compare group through the clinical observation to 100 routine patient systems simultaneously.
1, method
1.1 case is selected
1.1.1 diagnostic criteria
Abide by the diagnostic criteria of " the clinical research guidelines of new Chinese medicine treatment hemorrhoid ".
1.1.1.1 Western medicine diagnose standard (with reference to the diagnostic classification standard of national first anorectal academic conference formulation in 1975)
(1) symptom:
1. podex is hemorrhage just the time, or bleeds, or penetrates blood;
2. just the time or after the fatigue, hemorrhoid are deviate from outside the anus, can be from horizontal reset, or need manual reduction;
3. podex discomfort just the time, the companion weighs down pain.
(2) inspection: anus edge hemorrhoid redness, blood stasis becomes big when increasing abdominal pressure, and part patient's internal hemorrhoid is deviate from outside the anus.
(3) anoscopy: the bossed blood stasis of distal rectal, the hemorrhoid mucous hyperemia, or the companion is rotten to the corn.
In above-mentioned 3 all meeting (1) in 2 and (2), (3) 1, promptly diagnosable.
1.1.1.2 the classification of hemorrhoid
According to position, hemorrhoid piece place difference, can be divided into following 3 classes:
1) internal hemorrhoid: occur in the cirso-agglomerate of superior rectal vein clump, be positioned at more than the tooth trace, the surface is covered by mucous membrane of rectum.Be common in right front and right back 3 places, left side.
(2) external hemorrhoid: occur in the cirso-agglomerate of inferior rectal veins clump, be positioned at below the tooth trace, the surface is covered by anal canal skin.Simple external hemorrhoid sees around the anus, often gives prominence to outside because of intravenous thrombosis.Can be divided into:
Inflammatory external hemorrhoid: anus edge skin wrinkle wall projection, have inflammatory red, hot, swollen, pain to show, often and anal sinusitis, anal fissure concurrent.
Thrombosed external hemorrhoid: from the beginning of anus edge one side nuclear shape protuberance, red heat swells and ache, and lump is pale blue black then, or diabrosis or swell and ache is disappeared or thrombus organization gradually.
The varicosis external hemorrhoid: the subcutaneous swelling of anus edge behind the defecation, the vein group of visible varicose, rectal tenesmus, hypodynia, normal and internal hemorrhoid is concurrent.
(3) mixed hemorrhoid: because the upper and lower venous plexus of rectum coincide mutually, interact, thereby the hemorrhoid piece is positioned at about the tooth trace, the surface is covered by mucous membrane of rectum and anal canal skin simultaneously.
1.1.1.3 internal hemorrhoid by stages
The I phase: to have blood in stool.Have blood in stool and being divided into stool band blood, bleeding, penetrate blood.Anoscopy: have internal hemorrhoid to form hemorrhoid mucous hyperemia or erosion.
The II phase: internal hemorrhoid is deviate from during stool, and internal hemorrhoid can be from horizontal reset, sometimes with having blood in stool after an action of the bowels.Anoscopy: internal hemorrhoid is seen right front, right back and left side more.
The III phase: internal hemorrhoid is deviate from during stool, and internal hemorrhoid can not need to return with hand rest from horizontal reset after an action of the bowels.Anoscopy: how ringwise internal hemorrhoid often becomes with hemorrhoid below the tooth trace.
The IV phase: hemorrhoid are deviate from anus outer (often occurring with mixed hemorrhoid) at ordinary times.Anoscopy: except that internal hemorrhoid in the form of a ring, the following anal canal of tooth trace, anus edge also have obvious hemorrhoid to become.
Hemorrhoid such as inflammation often are thrombosis inflammatory hemorrhoid, incarceration internal hemorrhoid.
1.1.1.4 Chinese medical discrimination
The stagnancy of wind and heat card
Archorrhagia after an action of the bowels, color is scarlet, pruritus ani, it is not smooth to defecate, and General Symptoms is not obvious.
Syndrome of stagnant and jamming dampness-heat
Swelling and pain of anus, dry mouth with bitter taste, inappetence is hard and dry or constipated, and the urine yellow skin is bled in the time of just.
1.1.2 include the case standard in
According to drug function, with dialectical stagnancy of wind and heat card or the syndrome of stagnant and jamming dampness-heat of belonging to, the hemorrhoid patients of age between 18～65 years old included the checking case in.Concrete indication is: each phase internal hemorrhoid (, two, three, the fourth phase), mixed hemorrhoid belong to stagnancy of wind and heat card (hemorrhoidal hamorrhage) or syndrome of stagnant and jamming dampness-heat person, and the case of bleeding are arranged.The person does not list identifying object in not have the bleeding during checking.
1.1.3 get rid of case standard (comprising non-indication and rejecting standard)
1.1.3.1 hemorrhoid merge anal fistula, perianal abscess person,
1.1.3.2. suffer from anus colorectal cancer, rectal polyp, anal papilla tumor person.
1.1.3.3. intestinal infection disease.
1.1.3.4. the age, the gravid woman was to this medicine allergy sufferers at under-18s or over-65s.
1.1.3.5. be associated with serious primary disease such as cardiovascular, liver, kidney and hemopoietic system.
1.1.3.6. do not meet the standard of including in, not medication in accordance with regulations can't be judged curative effect or data not umbra sound curative effect or safety judgement person.
1.2. grouping, comparison
1.2.1. 200 examples are observed in this research altogether, wherein treatment group (T group) 100 examples, matched group (C group) 100 examples.
Divide three groups to observe respectively 1.2.2. will all observe case, wherein 70 examples (each 35 example of treatment group and matched group) are respectively observed by Jiangsu TCM Hospital and Nanjing Chinese Medicine Hospital, and 60 examples (treatment group and matched group respectively are 30 examples) are observed by Changzhou institute of traditional Chinese medicine.
1.2.3. controlled observation
Use the table of random number method and carry out random packet, controlled observation.The main therapeutical effect of observing the bleeding that the hemorrhoid hemostasis granules has each phase internal hemorrhoid, mixed hemorrhoid, and with the difference of former drug form therapeutical effect, and human body had no adverse reaction etc.
1.3. medicine specification, usage
1.3.1. trial drug: the hemorrhoid hemostasis granules, provide by the Tongrentang Pharmaceutical Factory, Nanjing, every bag 5 grams contain crude drug amount 6 grams.Usage: each 1 bag (5 gram), every day 3 times, 1 week of the course of treatment.Do not take any other medicative medicine during the treatment.
1.3.2. matched group: the oral haemorrhoids hemostatic pills, produce and every bottle of 60g is provided by the Tongrentang Pharmaceutical Factory, Nanjing.Usage: each 6 grams, every day 3 times, 1 week of the course of treatment.Do not take other any medicative medicines during the treatment.
1.4. observation caliber
1.4.1 curative effect determinate standard
Clinical cure: the disappearance of having blood in stool.
Produce effects: having blood in stool, (2 levels fall in the degree of having blood in stool in significantly minimizing; Or 1 level falls in the degree of having blood in stool, but amount of bleeding reduces more than or equal to 70%).
Effectively: the minimizing of having blood in stool (1 level falls in the degree of having blood in stool, or the degree of having blood in stool do not demote, but amount of bleeding reduces more than or equal to 30%, less than 70%).
Invalid: the degree of having blood in stool or amount of bleeding all do not have change.
The stage division 1.4.2. have blood in stool
0 grade: do not have and have blood in stool;
1 grade (light disease): toilet paper band blood;
2 grades (middle disease): bleed;
3 grades (serious symptom): penetrate blood.
1.4.3. judge the course of treatment
1.4.3.1. with took medicine for 1 week (7 days) is a course of treatment, judges therapeutic outcome.
1.4.3.2. onset time be meant the recovery from illness patient begin to take medicine to the shortest time of obtaining final curative effect (produce effects, effective, invalid all by 7 days calculating).
1.5. work out the special-purpose tabular form case history of clinical observation.
1.6. each checking unit specifies the personnel that possess respective capabilities, forms the clinical observation group and carries out the clinical verification observation.
2. clinical data
2.1 physical data
This test ended in April, 1998 from January, 1998,
Case source: outpatient's 132 examples, inpatient's 68 examples, totally 200 examples, wherein 100 examples are organized in treatment, matched group 100 examples.
The sex composition of table 1 200 routine cases
| Grouping | Sex | Add up to | |
| The man | The woman | ||
| The treatment group | 64 | 36 | 100 |
| Matched group | 56 | 44 | 100 |
The age structure unit of table 2 200 routine cases: year
| Grouping | Age (year) | Add up to | |||||
| 18～ | 20～ | 30～ | 40～ | 50～ | 60～65 | ||
| The treatment group | 1 | 11 | 18 | 25 | 22 | 23 | 100 |
| Matched group | 0 | 8 | 22 | 32 | 21 | 17 | 100 |
The occupation of table 3 200 routine cases constitutes
| Grouping | Occupation | Add up to | X2 | |||
| The workman | The peasant | The cadre | Other | |||
| The treatment group | 45 | 15 | 27 | 13 | 100 | 4.34 |
| Matched group | 58 | 8 | 22 | 12 | 100 | |
The diagnosis of table 4 200 routine cases
| Grouping | Diagnosis | Add up to | X2 | |||
| The first phase internal hemorrhoid | The second phase internal hemorrhoid | Stage | Mixed hemorrhoid | |||
| The treatment group | 11 | 16 | 4 | 69 | 100 | 1.02 |
| Matched group | 10 | 14 | 2 | 74 | 100 | |
The pattern of syndrome of table 5 200 routine cases
| Grouping | Pattern of syndrome | Add up to | X2 |
| Add up to | 74 | 15 | 8 | 3 | 100 | |
| Matched group | Heavy | 13 | 11 | 4 | 1 | 29 |
| In | 46 | 4 | 5 | 2 | 57 | |
| Gently | 11 | 0 | 2 | 1 | 14 | |
| Add up to | 70 | 15 | 11 | 4 | 100 |
Through Ridit check (U=5.991), significant difference (P＜0.05) is arranged between the state of an illness weight of treatment group and the curative effect, heavy according to the treatment group state of an illness, in, light cure rate is respectively 53.3%, 81.8%, 86.7%, total effective rate is respectively 93.3%, 98.2%, 100%, the curative effect and the state of an illness are inverse relation, and promptly state of an illness weight person is than state of an illness the lighter weak curative effect.But heavy to the state of an illness through between Ridit check treatment group and matched group, in, light curative effect there was no significant difference (the U value is respectively 2.45,0.04,0.03, and the P value is all greater than 0.05).
2.2.1.3 the relation of TCM Syndrome Type and curative effect
Relation between table 9, TCM Syndrome Type and curative effect relatively
| Grouping | Pattern of syndrome | Cure | Produce effects | Effectively | Invalid | Add up to |
| The treatment group | Stagnancy of wind and heat | 37 | 19 | 2 | 3 | 51 |
| Stagnation of damp-heat | 37 | 6 | 6 | 0 | 49 | |
| Matched group | Stagnancy of wind and heat | 38 | 9 | 2 | 3 | 52 |
| Stagnation of damp-heat | 32 | 6 | 9 | 1 | 48 |
Analyze through Ridit, treatment is organized between different pattern of syndrome aspect curative effect, there was no significant difference (U=0.53, P＞0.05); Different pattern of syndrome there was no significant difference (U=1.34, P＞0.05) between curative effect of treatment group and matched group.
2.2.1.4 the relation between Western medicine diagnose and curative effect
Relation between table 10, Western medicine diagnose and curative effect relatively
| Grouping | Western medicine diagnose | Cure | Produce effects | Effectively | Invalid | Add up to |
| The treatment group | The internal hemorrhoid first phase | 7 | 2 | 1 | 1 | 11 |
| The internal hemorrhoid second phase | 12 | 3 | 1 | 0 | 16 | |
| Three phases of internal hemorrhoid | 3 | 0 | 1 | 0 | 4 | |
| Mixed hemorrhoid | 52 | 10 | 5 | 2 | 69 | |
| Matched group | The internal hemorrhoid first phase | 9 | 0 | 1 | 0 | 10 |
| The internal hemorrhoid second phase | 11 | 2 | 1 | 0 | 14 | |
| Three phases of internal hemorrhoid | 2 | 0 | 0 | 0 | 2 |
| Mixed hemorrhoid | 48 | 13 | 9 | 4 | 74 |
Learn by statistics and handle, the treatment group is its curative effect there was no significant difference (Ridit analyzes, U=1.29, P＞0.05) aspect different Western medicine diagnoses.
3.2.2 onset time
Table 11, two groups of recovery from illness patients' onset time
| Grouping | Onset time (my god) | The example number | t | P |
| The treatment group | 5.04±1.38 | 74 | 0.82 | ＞0.05 |
| Matched group | 4.85±1.37 | 70 |
Recovery from illness patient's the shortest onset time is 2 days, and the longest is 7 days, indicates two groups of recovery from illness patients' onset time there was no significant difference (U=0.82 through the t check, P＞0.05), because to take medicine 7 days is a course of treatment, observe the curative effect is so be 7 days non-recovery from illness patient's the course of treatment.
3.2.3 therapeutic effect to the blood stasis sign
Table 12, to the therapeutic outcome of blood stasis sign
| Sign | Grouping | Disappear (%) | Improve (%) | No change (%) | Add up to |
| Congested | The treatment group | 80(80.0％) | 16(16.0％) | 4(4.0％) | 100 |
| Matched group | 69(69.0％) | 16(16.0％) | 15(15.0％) | 100 | |
| Edema | The treatment group | 45(95.7％) | 1(2.1％) | 1(2.1％) | 47 |
| Matched group | 33(86.8％) | 1(2.6％) | 4(10.5％) | 38 | |
| Rotten to the corn | The treatment group | 11(91.7％) | 0 | 1(8.3％) | 12 |
| Matched group | 9(90.0％) | 0 | 1(10.0％) | 10 | |
| Ulcer | The treatment group | 2(66.7％) | 0 | 1(33.3％) | 3 |
| Matched group | 2(100％) | 0 | 0 | 2 |
Two groups of curative effects are learned processing (Ridit check) by statistics, to the effect (the U value is respectively 1.807,0.513,0.043,0.33) of blood stasis sign, hyperemia, edema, erosion, ulcer, and there was no significant difference (the P value is all greater than 0.05) between two values.
3.2.4 therapeutic effect to the disease of holding concurrently
3.2.4.1 therapeutic effect to pruritus ani
Table 13, to the therapeutic effect of pruritus ani
| Grouping | Disappear (%) | Improve (%) | Invalid (%) | Add up to |
| The treatment group | 43(84.3％) | 7(13.7％) | 1(2.0％) | 51 |
| Matched group | 42(80.8％) | 9(17.3％) | 1(1.9％) | 52 |
As can be seen from the above table, the disappearance rate of hemorrhoid hemostasis granules treatment pruritus ani reaches 84.3%, improves above rate and reaches 98.0%.Show minimum percentage rate difference table, two groups of curative effect there was no significant differences (P＞0.05) through looking into two percentage rate difference.
3.2.4.2 to swelling and pain of anus therapeutic effect
Table 14, to the therapeutic effect of swelling and pain of anus
| Grouping | Disappear (%) | Improve (%) | Invalid (%) | Add up to |
| The treatment group | 45(91.8％) | 4(8.2％) | 0 | 49 |
| Matched group | 42(87.5％) | 6(12.5％) | 0 | 48 |
As can be seen from the above table, the hemorrhoid hemostasis granules adds up to 100% to disappearance, the improvement rate of swelling and pain of anus, and wherein disappearance rate is 91.8%.Show minimum percentage rate difference table, there was no significant difference between two groups of curative effects (P＞0.05) through looking into two percentage rate difference.
3.2.4.3 to the therapeutic effect of being hard and dry
Table 15, therapeutic effect to being hard and dry
| Grouping | Disappear (%) | Improve (%) | Invalid (%) | Add up to |
| The treatment group | 14(82.4％) | 3(17.6％) | 0 | 17 |
| Matched group | 17(94.4％) | 1(5.6％) | 0 | 48 |
As can be seen from the above table, the hemorrhoid hemostasis granules adds up to 100% to disappearance, the improvement rate of being hard and dry, and wherein disappearance rate is 82.4%.Show minimum percentage rate difference table, two groups of curative effect there was no significant differences (P＞0.05) through looking into two percentage rate difference.
3.2.4.4 to the not smooth therapeutic effect of stool
Table 16, to the not smooth therapeutic effect of stool
| Grouping | Disappear (%) | Improve (%) | Invalid (%) | Add up to |
| The treatment group | 16(94.4％) | 0 | 1(5.9％) | 17 |
| Matched group | 15(93.8％) | 1(6.2％) | 0 | 16 |
As can be seen from the above table, the hemorrhoid hemostasis granules does not freely have defecating feces excretion preferably to stool, and disappearance, improvement rate add up to 100%, and wherein disappearance rate is 94.1%.Show minimum percentage rate difference table, there was no significant difference between two groups of curative effects (P＞0.05) through looking into two percentage rate difference.
3.3 safety observed result
The treatment group is observed case 100 examples, does not find obvious toxicity.Tried to have in the case 30 routine cases, " all have a blood test before and after the hemorrhoid hemostasis granules routine, platelet count, routine urinalysis, stool routine examination, liver function (paddy third enzyme, r-glutamyl transpeptidase), renal function (blood urea nitrogen, creatinine), Electrocardioscopy, its result is equal Non Apparent Abnormality before and after treatment taking.
3, model case
(1) Wang Guixiang, the woman, 50 years old, numbering was economized T011.Tell the gap outbreak 7 years of having blood in stool, nearly outbreak increased the weight of 7 days.Penetrate blood when now defecating, bleed, color is scarlet, measures about 30ml, and the thing that swells in the anus in the time of is just deviate from; Return voluntarily after an action of the bowels and receive in the anus.The companion stool is not smooth, just meaning sense not to the utmost, and anus slightly swells and ache.Red tongue, yellow, greasy and thin fur, the little number of soft pulse.The podex training is checked: calculi position 3,7-8,10-11 point, stride the swollen thing protuberance of tooth trace, about respectively 1 * 1 * 1cm, 1 * 1 * 1.5cm, 1 * 1 * 2.0cm size.Congested, edema is obvious, and is slight rotten to the corn, do not see ulcer, do not see the petechia.Yu Wei looks into and other is unusual.AD: the traditional Chinese medical science: internal hemorrhoid, stagnation of damp-heat type.Doctor trained in Western medicine: internal hemorrhoid second phase.According to medical history and whole body situation, meet the requirement of clothes hemorrhoid hemostasis granules, promptly give clothes hemorrhoid hemostasis granules, 1 time 5 gram, 3 times on the 1st from February 23rd, 1998.Behind the medicine 1 day, to have blood in stool and reduce gradually, swelling and pain of anus alleviates, disappearances of having blood in stool in 4 days behind the medicine, the swelling and pain of anus disappearance, defecation is unobstructed.Look into former hemorrhoid mucous hyperemia, edema is rotten to the corn to disappear.There is not any discomfort in the drug administration process.Have a blood test routine, routine urinalysis, stool routine examination, liver function, renal function, Electrocardioscopy is all no abnormal before and after the treatment.The result is judged as recovery from illness.
(2) open the faithful and upright person, the male, 40 years old, the workman came me to examine prescription on individual diagnosis by gate from March 22nd, 1998, numbering city T044.Stool is penetrated blood after patient's readme cause fatigue in ten days, and color is scarlet, and the about 15ml of each amount deviates from light red tongue with the swollen thing of anus simultaneously; The floating pulse string.Anus toposcopy, 3,5 of calculi positions are located to tie tooth and are become swollen thing grand, mucous hyperemia, diagnosis on inspection: the traditional Chinese medical science: mixed hemorrhoids, stagnancy of wind and heat card; Doctor trained in Western medicine: mixed hemorrhoid, give the hemorrhoid hemostasis granules, 5g, three times on the one.Serve on seven days, the back the 3rd day of taking medicine, hemorrhage obvious minimizing was taken medicine back five days, stopped bleeding, the swollen thing of anus is not seen, and mucous hyperemia disappears and accuses more.
(3) Liu Yongzhu, the woman, 64 years old, the peasant numbered normal T050.The main suit has thing to deviate to accompany hemorrhage the outbreak repeatedly 10 years in the anus just the time.Nearly outbreak increased the weight of 5 days, penetrated blood in the time of just, hemorrhage once about 15ml, and the thing that swells in the anus in the time of is just deviate from, after an action of the bowels Hui Na voluntarily.Companion's pruritus ani, be hard and dry, red tongue, yellow and thin fur, stringy and thready pulse, anus training check that 3,7,11 of calculi positions stride the swollen thing protuberance of tooth trace, and be congested, edema is obvious.AD: the traditional Chinese medical science: internal hemorrhoid, the stagnancy of wind and heat card, doctor trained in Western medicine: the internal hemorrhoid second phase, from March 21st, 1998, give " hemorrhoid hemostasis granules " 5 to restrain/time, 3 times on the 1st, serve on seven days.The 2nd day amount of bleeding in back of taking medicine obviously reduces, the hemorrhage disappearance of defecating in back four days of taking medicine, and pruritus ani disappears, and looks into former hemorrhoid mucous hyperemia, edema disappears and accuses more.
The patient does not have any discomfort in drug administration process, all make blood, urine, stool routine examination and electrocardiogram, liver function, kidney function test before and after the treatment, all no abnormal prompting of secondary check report.
Each phase internal hemorrhoid of Drug therapy of the present invention, mixed hemorrhoid stool hemorrhage, through clinical 100 example tests, its cure rate is respectively 74%, the above rate of produce effects is respectively 89%, total effective rate is respectively 97%.
Claims (6)
1, a kind of Chinese medicine preparation for the treatment of bleeding hemorrhoids is characterized in that pressing column weight amount proportioning raw material and makes:
1～3 part of 1～3 part of Herba Agrimoniae of 1～3 portion of Radix Sanguisorbae of 1～3 portion of Cacumen Platycladi of 1～3 part of Pericarpium Citri Reticulatae of 1～3 portion of Herba Schizonepetae of Flos Sophorae;
Above Six-element, Flos Sophorae is made solvent with the ethanol of 0%-95%, adopts percolation or infusion process, is prepared into fluid extract; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted volatile oil, and volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 1～20, and the aqueous solution behind extraction volatile oil device is in addition deposited; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi is extracted the medicinal residues behind the volatile oil, with Radix Sanguisorbae, Herba Agrimoniae decocts with water 1-4 time, each 0.5～3.5 hour, collecting decoction filtered, filtrate merges with the aqueous solution that extracted volatile oil, relative density is 1.01～1.35 when being concentrated into hot thermometric degree and being 20～100 ℃, and cooling adds ethanol and transfers and contain the alcohol amount to 0%～95%, place more than 0 hour, get supernatant, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and relative density is 1.01～1.40 clear paste when being concentrated into hot thermometric degree and being 20～100 ℃, and qinghuo reagent adds adjuvant, the inclusion complex of volatile oil, mix homogeneously is made granule, tablet or capsule.
2, the Chinese medicine preparation of treatment bleeding hemorrhoids according to claim 1 is characterized in that making by following weight proportion crude drug: 1.5～2.5 parts of 1.5～2.5 parts of Herba Agrimoniaes of 1.5～2.5 portions of Radix Sanguisorbaes of 1.5～2.5 portions of Cacumen Platycladis of 1.5～2.5 parts of Pericarpium Citri Reticulataes of 1.5～2.5 portions of Herba Schizonepetae of Flos Sophorae; Make by the described method for making of claim 1.
3, the Chinese medicine preparation of treatment bleeding hemorrhoids according to claim 1 is characterized in that making by following weight proportion crude drug: 2 parts of 2 parts of Herba Agrimoniaes of 2 portions of Radix Sanguisorbaes of 2 portions of Cacumen Platycladis of 2 parts of Pericarpium Citri Reticulataes of 2 portions of Herba Schizonepetae of Flos Sophorae;
Above Six-element medicine, Flos Sophorae is made solvent with the ethanol of 50%-90%, adopts percolation or infusion process, is prepared into fluid extract; Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted volatile oil, and volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 5～10, and the aqueous solution behind extraction volatile oil device is in addition deposited; Medicinal residues and Radix Sanguisorbae, Herba Agrimoniae that Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted behind the volatile oil decoct with water 2-3 time, each 1.5～3.5 hours, collecting decoction, filter, aqueous solution behind filtrate and the said extracted volatile oil merges, relative density is 1.15～1.30 when being concentrated into hot thermometric degree and being 40～70 ℃, cooling, add the ethanol accent and contain the alcohol amount, place more than 12 hours, get supernatant to 50%～80%, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and relative density is 1.20～1.40 clear paste when being concentrated into hot thermometric degree and being 40～70 ℃; Qinghuo reagent, the inclusion complex of adding adjuvant, volatile oil, mix homogeneously is made granule, tablet or capsule.
4, the Chinese medicine preparation of treatment bleeding hemorrhoids according to claim 3 is characterized in that:
Flos Sophorae is made solvent with 70% ethanol, uses percolation, makes the Flos Sophorae fluid extract routinely; Extract the volatile oil of Herba Schizonepetae, Pericarpium Citri Reticulatae and Cacumen Platycladi, volatile oil beta-schardinger dextrin-inclusion, the ratio of volatile oil and beta-schardinger dextrin-are 1: 8, and the aqueous solution behind extraction volatile oil device is in addition deposited; Medicinal residues and Radix Sanguisorbae, Herba Agrimoniae that Herba Schizonepetae, Pericarpium Citri Reticulatae, Cacumen Platycladi are extracted behind the volatile oil decoct with water 2 times, each 2 hours, collecting decoction, filter, aqueous solution behind filtrate and the said extracted volatile oil merges, be 1.25～1.30 to density when being concentrated into hot thermometric degree and being 50 ℃, cooling, add the ethanol accent and contain the alcohol amount, place more than 24 hours, get supernatant to 60%, reclaim ethanol, add the Flos Sophorae fluid extract, continue to reclaim ethanol, and relative density is 1.30～1.33 clear paste when being concentrated into hot thermometric degree and being 50 ℃; Qinghuo reagent, the inclusion complex of adding adjuvant, volatile oil, mix homogeneously is made granule, tablet or capsule.
5, the Chinese medicine preparation of treatment bleeding hemorrhoids according to claim 4 is characterized in that used adjuvant is a kind of in starch, dextrin, protein sugar, the Mel, or mixture.
6, treatment bleeding hemorrhoids Chinese medicine preparation according to claim 4 is characterized in that described preparation is a granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02113007 CN1203877C (en) | 2002-05-15 | 2002-05-15 | Chinese medicine preparation for curing hemorrhoidal bleeding |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02113007 CN1203877C (en) | 2002-05-15 | 2002-05-15 | Chinese medicine preparation for curing hemorrhoidal bleeding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1457811A CN1457811A (en) | 2003-11-26 |
| CN1203877C true CN1203877C (en) | 2005-06-01 |
Family
ID=29426408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02113007 Expired - Lifetime CN1203877C (en) | 2002-05-15 | 2002-05-15 | Chinese medicine preparation for curing hemorrhoidal bleeding |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1203877C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422536B (en) * | 2008-12-02 | 2011-04-27 | 黄尊显 | Preparation method of traditional Chinese medicine for treating excessive-heat intestinal dryness type internal hemorrhoid |
| CN105395915A (en) * | 2015-11-10 | 2016-03-16 | 夏放军 | Traditional Chinese medicine decocted extract for treating intestinal wind and preparation method thereof |
| CN112353864A (en) * | 2020-12-14 | 2021-02-12 | 吉林省长源药业有限公司 | Traditional Chinese medicine composition for treating haemorrhoids bleeding and preparation method thereof |
-
2002
- 2002-05-15 CN CN 02113007 patent/CN1203877C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1457811A (en) | 2003-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872437B (en) | Special-disease calculus-removing decoction for treating renal calculus | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN105902558B (en) | A kind of pharmaceutical composition and its preparation method and application | |
| CN1203877C (en) | Chinese medicine preparation for curing hemorrhoidal bleeding | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN1069043C (en) | Medicine for treatment of lithiasis | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN104147110A (en) | Traditional Chinese medicine formula and compound preparation for treating haemorrhoids | |
| CN104888062A (en) | Drug for treating liver Yang hyperactivity type hypertensive disease and preparation method therefor | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN115475190B (en) | A kind of traditional Chinese medicine composition for treating ureteral calculi | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN1238034C (en) | Traditional Chinese medicine compostion for treating intestinal disease | |
| CN109833371B (en) | Traditional Chinese medicine composition for treating constipation after hemorrhoids and fistula operation and preparation method and application thereof | |
| CN107875189B (en) | A pharmaceutical composition for treating upper gastrointestinal hemorrhage, and its preparation method | |
| CN100512831C (en) | Medicament for gastrointestinal tract operation front intestinal tract cleaning | |
| CN1088378C (en) | Oral Chinese medicine liquid for treating chronic superficial gastritis and its preparation | |
| CN107137456A (en) | It is a kind of to treat medicine of chronic osteomyelitis and its preparation method and application | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN1299752C (en) | Traditional Chinese medicine capsule for treating urinary calculus and its prepn. method | |
| CN119837819A (en) | Paederia scandens suppository and preparation method thereof | |
| CN105477418A (en) | Traditional Chinese medicinal preparation for treating urinary system infection | |
| CN101066306A (en) | Chinese medicine composition for treating gynecologic hemorrhage pile hemorrhage and nasal hemorrhage and its prepn | |
| CN106266970B (en) | A kind of Chinese medicine composition treated production and cause endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050601 |
|
| CX01 | Expiry of patent term |